**Correction to:** *British Journal of Cancer* (2007) **96**, 1293--1301. doi:10.1038/6603696

In the abstract of the above paper, a peptide with correct sequence (TLMKKDKYTL) is mentioned. This sequence should also appear in [Table 1](#tbl1){ref-type="table"} as the sequence of peptide 60031. Unfortunately, an incorrect sequence (ALSPASSRSV) was included in [Table 1](#tbl1){ref-type="table"} (all other data in the respective line of the table are correct and refer to peptide TLMKKDKYTL).

The corrected [Table 1](#tbl1){ref-type="table"} is shown below.

###### 

Prediction of HLA-A^\*^0201-restricted SOX2-derived peptides and determination of binding affinities by a competition assay

  **Peptide**    **Position^a^**   **Sequence**   **MW**   **Length^b^**   **Score**   **rBA (%)^c^**
  ------------- ----------------- -------------- -------- --------------- ----------- ----------------
  60029             275--283        SMYLPGAEV     965.5          9            26            97.2
  60030             131--139        LLAPGGNSM     858.4          9            25            80.0
  60031             118--127        TLMKKDKYTL    1239.7        10            24            43.3

MW=molecular weight; rBA=relative binding affinity.

The given numbers indicate the position of the peptide in the amino-acid sequence of SOX2.

Number of amino acids.

The relative binding affinities were determined by comparing the inhibition of the reporter peptide binding by the analysed peptides in relation to the inhibition obtained with a positive control peptide, which was set as 100%. The positive control peptide was YLLPAIVHI from RNA helicase p72 and the reporter peptide was ILK(FITC)EPVHGV from HIV-1 reverse transcriptase. All peptides were used at a concentration of 10 *μ*[M]{.smallcaps}.
